MX2023013537A - Metodo de tratamiento de la enfermedad de alzheimer. - Google Patents
Metodo de tratamiento de la enfermedad de alzheimer.Info
- Publication number
- MX2023013537A MX2023013537A MX2023013537A MX2023013537A MX2023013537A MX 2023013537 A MX2023013537 A MX 2023013537A MX 2023013537 A MX2023013537 A MX 2023013537A MX 2023013537 A MX2023013537 A MX 2023013537A MX 2023013537 A MX2023013537 A MX 2023013537A
- Authority
- MX
- Mexico
- Prior art keywords
- alzheimer
- disease
- treatment
- hydrochloride
- inden
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 229960003135 donepezil hydrochloride Drugs 0.000 abstract 1
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960000967 memantine hydrochloride Drugs 0.000 abstract 1
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190299P | 2021-05-19 | 2021-05-19 | |
| US202163192398P | 2021-05-24 | 2021-05-24 | |
| US202263331011P | 2022-04-14 | 2022-04-14 | |
| PCT/US2022/030020 WO2022246059A1 (en) | 2021-05-19 | 2022-05-19 | Method of treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013537A true MX2023013537A (es) | 2024-02-06 |
Family
ID=84104208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013537A MX2023013537A (es) | 2021-05-19 | 2022-05-19 | Metodo de tratamiento de la enfermedad de alzheimer. |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20220370443A1 (https=) |
| EP (1) | EP4340834A4 (https=) |
| JP (1) | JP2024518455A (https=) |
| KR (1) | KR20240021760A (https=) |
| AU (1) | AU2022275939A1 (https=) |
| CA (1) | CA3217579A1 (https=) |
| MX (1) | MX2023013537A (https=) |
| WO (1) | WO2022246059A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60006145T2 (de) * | 1999-07-30 | 2004-06-09 | Zenyaku Kogyo K.K. | Azaindolizinon-derivate und agenzien zur verbesserung der kognitiver fähigkeiten,die dieselben als aktive inhaltstoffe enthalten |
| JP2012512173A (ja) * | 2008-12-15 | 2012-05-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アミロイド前駆体タンパク質の切断を誘導して新規断片を形成させる方法 |
| CN102573839A (zh) * | 2009-05-11 | 2012-07-11 | 加利福尼亚大学董事会 | 降低泛素化蛋白水平的方法 |
| WO2012094612A1 (en) * | 2011-01-07 | 2012-07-12 | Zenyaku Kogyo Kabushikikaisha | Method of treating essential tremor |
-
2022
- 2022-05-19 MX MX2023013537A patent/MX2023013537A/es unknown
- 2022-05-19 EP EP22805475.5A patent/EP4340834A4/en active Pending
- 2022-05-19 JP JP2023568654A patent/JP2024518455A/ja active Pending
- 2022-05-19 US US17/748,451 patent/US20220370443A1/en not_active Abandoned
- 2022-05-19 CA CA3217579A patent/CA3217579A1/en active Pending
- 2022-05-19 AU AU2022275939A patent/AU2022275939A1/en active Pending
- 2022-05-19 WO PCT/US2022/030020 patent/WO2022246059A1/en not_active Ceased
- 2022-05-19 KR KR1020237039101A patent/KR20240021760A/ko active Pending
-
2024
- 2024-01-23 US US18/420,250 patent/US20240156812A1/en not_active Abandoned
-
2025
- 2025-05-19 US US19/211,429 patent/US20250375444A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022275939A1 (en) | 2023-11-16 |
| CA3217579A1 (en) | 2022-11-24 |
| WO2022246059A1 (en) | 2022-11-24 |
| EP4340834A1 (en) | 2024-03-27 |
| US20220370443A1 (en) | 2022-11-24 |
| JP2024518455A (ja) | 2024-05-01 |
| US20250375444A1 (en) | 2025-12-11 |
| EP4340834A4 (en) | 2025-04-02 |
| KR20240021760A (ko) | 2024-02-19 |
| US20240156812A1 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200100619A (et) | Asendatud bensimidasoolid, nende saamine ning kasutamine ravimi valmistamiseks, mis on ette nähtud NFkB aktiivsuse suurenemisest tingitud haiguste profülaktikaks ja raviks | |
| CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| ATE405269T1 (de) | Cyclohexylverbindungen als ccr5-antagonisten | |
| ATE384724T1 (de) | Cyclopropylverbindungen als ccr5 antagonisten | |
| SE0202462D0 (sv) | Novel use | |
| EP2270511A3 (en) | Method of therapy | |
| TW200505416A (en) | Bi-aryl compound having immunosuppressive activity | |
| FI3840753T3 (fi) | Migalastaatti käytettäväksi fabryn taudin hoitomenetelmissä potilailla joilla on gla-geenin mutaatio | |
| MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| SE0202429D0 (sv) | Novel Compounds | |
| ITMI20022674A1 (it) | Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione. | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| ZA202309001B (en) | Abhd6 antagonist | |
| MX362830B (es) | Agente terapeutico o profilactico para enfermedades del tracto biliar. | |
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| MX2025012741A (es) | Composiciones farmaceuticas orales | |
| MX2023013537A (es) | Metodo de tratamiento de la enfermedad de alzheimer. | |
| EA200700178A1 (ru) | Пептид, обладающий стресспротекторным действием, фармацевтическая композиция на его основе и способ ее применения | |
| TW200503709A (en) | Itching treating agent containing piperidine derivative as active ingredient | |
| EA200700433A1 (ru) | Производные бетулинола в качестве агентов против вич (вируса иммунодефицита человека) | |
| EE200200549A (et) | Jagatud doosi teraapia veresooni kahjustava aktiivsusega | |
| UA85389C2 (ru) | Применение циклических биоизостеров производных пуриновой системы для лечения расстройств, вызванных нарушениями нитрэргической и дофаминергической систем | |
| DE60104589D1 (de) | Therapeutisches Mittel zur Behandlung von Dermatitis | |
| WO2024182753A3 (en) | Methods for treating influenza infections |